sunitinib krka 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula - sunitinib
sunitinib krka 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula - sunitinib
sunitinib krka 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
lusmose 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
sunitinib pharmascience 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula
sunitinib pharmascience 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula
sunitinib pharmascience 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
stivarga
bayer pharma ag - regorafenib - kolorektalne neoplazme - antineoplastic agents, protein kinase inhibitors - stivarga je označen kot monotherapy za zdravljenje odraslih bolnikov z:metastatskega kolorektalnega raka (crc), ki so bili predhodno zdravljeni z, ali se ne štejejo kandidati, ki so na voljo terapije - ti vključujejo fluoropyrimidine temeljijo na kemoterapijo, anti-vegf terapije in anti-egfr terapije;unresectable ali metastatskim gastrointestinal stromal tumorjev (bistvo), ki je napredoval na ali so nestrpni, da se pred zdravljenjem z imatinib in sunitinib;hepatocellular carcinoma (hcc), ki so bili predhodno zdravljeni z sorafenib.
torisel
pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastična sredstva - ledvične celice carcinomatorisel je določen za prvo linijo za zdravljenje odraslih bolnikov z napredovalim ledvičnim-cell carcinoma (rkc), ki so najmanj tri od šestih prognostic dejavniki tveganja. plašč-celice lymphomatorisel je indiciran za zdravljenje odraslih bolnikov z relapsed in / ali ognjevzdržni plašč-celični limfom (mcl).